Pre-Emptive Parecoxib Sodium for Pain Control During CT-Guided Lung Nodule Localization

Inclusion Criteria: * Voluntarily agreed to participate in the study and signed the informed consent form approved by the Ethics Committee. * Male or female adult patients aged 18 years or older. * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) scheduled for Video-Assisted Thoracoscopic Surgery (VATS). * Requires preoperative CT-guided hook wire localization of lung nodules. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * American Society of Anesthesiologists (ASA) physical status classification of I or II. * Fully conscious with no psychiatric or neurological disorders, and capable of fully understanding and correctly using the Visual Analog Scale (VAS) for pain assessment. Exclusion Criteria: * Known history of hypersensitivity to parecoxib sodium, other COX-2 inhibitors, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs). * History or presence of active peptic ulcer disease, gastrointestinal bleeding, or gastrointestinal perforation. * Severe cardiovascular diseases, including but not limited to unstable angina, history of myocardial infarction within the past 6 months, severe arrhythmias, or poorly controlled hypertension. * Coagulation disorders with a bleeding tendency (e.g., hemophilia) or currently receiving full-dose anticoagulation therapy, which the investigator believes may significantly increase the bleeding risk of the hook wire localization. * Severe, uncontrolled pulmonary diseases (e.g., severe chronic obstructive pulmonary disease \[COPD\], interstitial pneumonia) that the investigator believes pose an unacceptable risk for the procedure. * Currently using other analgesic medications that cannot be discontinued during the study period. * Any other conditions that, in the investigator's judgment, might interfere with the outcome assessment or increase the risk to the subject.